ClinicalTrials.gg
CompletedNCT01498640Updated Oct 5, 2017Results posted

Retreatment of Recurrent Dupuytren's Contractures

A Phase 4 interventional study of Collagenase clostridium histolyticum in Dupuytren's Disease, sponsored by Endo Pharmaceuticals. Completed at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.

Enrollment
11th of 17
52 · median 76
Started
2012
with 3 others
Phase 4
7 of 17
none open now
Registered
9th of 17
by date
Lead sponsor
6 of 17
Endo Pharmaceuticals

Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 11th largest by enrollment, is one of 4 that started in 2012, is one of 7 in phase 4, and was the 9th registered.

Dupuytren Contracture

78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.

Browse Dupuytren Contracture studies →

Open to participants now

None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Microbial Collagenase in Dupuytren Contracture as a file.
02

Study summary

The objectives of this study are to assess the safety and efficacy of AA4500 in the retreatment of recurrent contractures in joints that were effectively treated with AA4500 in a previous Auxilium-sponsored Phase 3 study.

Read the detailed description

Open-label, Phase 4 study in subjects who are currently participating in the long-term follow-up study (ie, AUX-CC-860) in the United States, Australia, or Europe and who have recurrence of contracture (ie, joint contracture increases by at least 20 degrees compared with the Day 30 value after the last injection in a Phase 3 Auxilium-sponsored study and a palpable cord present) in a joint that was effectively treated (ie, reduction in contracture to 5 degrees or less 30 days after the last injection) with AA4500 in a Phase 3 Auxilium-sponsored study.

Subjects who experience recurrence of contracture in one or more effectively treated joints may be enrolled in this retreatment study after the investigator determines subject eligibility and after informed consent has been obtained. The investigator will treat the cord affecting the recurrent joint with up to three injections. Only one recurrent joint will be treated in this study.

03

Conditions studied

  • Dupuytren's Disease

Keywords

  • XIAFLEX
  • XIAPEX
  • Dupuytren's disease
  • contracture
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written
  2. Be currently participating in the AUX-CC-860 follow-up study
  3. Have at least one joint with all of the following:

    • The joint was effectively treated (had a correction to 5 degrees or less at the Day 30 evaluation after the last injection of AA4500) in a previous Auxilium Phase 3 study
    • The effectively treated joint has an increase in contracture of at least 20 degrees compared with the Day 30 value after the last injection of AA4500 in a previous Auxilium Phase 3 study
    • A palpable cord is present in the joint to be treated
  4. Be able to comply with the study visit schedule as specified in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Is a pregnant or lactating female or female intending to become pregnant during the study
  2. Has to AA4500 or any of the AA4500
  3. Is currently receiving or plans to receive anticoagulant medication or has received anticoagulant medication (except for equal to or less than 150 mg aspirin daily and over-the-counter nonsteroidal antiinflammatory drugs [NSAIDs]) within 7 days before injection of AA4500
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    XIAFLEX/XIAPEX MP Joint

    Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord

    Biological: Collagenase clostridium histolyticum

  • Experimental
    XIAFLEX/XIAPEX PIP Joint

    Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord

    Biological: Collagenase clostridium histolyticum

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Success

    Clinical success defined as reduction in fixed-flexion contracture to less than or equal to 5 degrees 30 days after the last injection of AA4500

    Time frame: 30 days after last injection

  2. Percent Change From Baseline in Degree of Contracture

    Change in fixed-flection contracture measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees

    Time frame: Baseline and 30 days after last injection

  3. Change in Range of Motion

    Range of motion defined as difference between full flexion angle and full extension angle expressed in degrees

    Time frame: Baseline and 30 days after last injection

Secondary outcomes

  1. Physician Global Assessment of Improvement

    Physician global assessment of change (improvement) in subject's Dupuytren's contracture

    Time frame: 30 days after last injection

  2. Subject Global Assessment of Satisfaction

    Subject global assessment of overall treatment satisfaction

    Time frame: 30 days after last injection

  3. Recurrence of Contracture

    Recurrence of contracture in the joint at day 365 that was successfully treated 30 days after last injection assessed. Recurrence was defined as 20 degree or greater increase of contracture of the treated joint at day 365 or medication intervention of the treated joint between the 2 time points.

    Time frame: Day 365

07

Results

Posted Feb 20, 2015

Participant flow

Participant flow — Overall Study
MilestoneXIAFLEX/XIAPEX
Started52
Completed47
Not completed5
Withdrew: Lost to follow-up1
Withdrew: Death1
Withdrew: Other3

Outcome measures

PrimaryClinical Success

Clinical success defined as reduction in fixed-flexion contracture to less than or equal to 5 degrees 30 days after the last injection of AA4500

Time frame:
30 days after last injection
Reported as:
Number · percentage of particpants
Clinical Success
percentage of particpantsXIAFLEX/XIAPEX MP JointXIAFLEX/XIAPEX PIP Joint
Clinical Success64.5 (45.37 to 80.77)45.0 (23.06 to 68.47)
PrimaryPercent Change From Baseline in Degree of Contracture

Change in fixed-flection contracture measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees

Time frame:
Baseline and 30 days after last injection
Reported as:
Mean · percentage of contracture change
Percent Change From Baseline in Degree of Contracture
percentage of contracture changeXIAFLEX/XIAPEX MP JointXIAFLEX/XIAPEX PIP Joint
Percent Change From Baseline in Degree of Contracture83.24 ± 24.27569.10 ± 26.776
PrimaryChange in Range of Motion

Range of motion defined as difference between full flexion angle and full extension angle expressed in degrees

Time frame:
Baseline and 30 days after last injection
Reported as:
Mean · degrees
Change in Range of Motion
degreesXIAFLEX/XIAPEX MP JointXIAFLEX/XIAPEX PIP Joint
Change in Range of Motion31.4 ± 17.5226.8 ± 17.39
SecondaryPhysician Global Assessment of Improvement

Physician global assessment of change (improvement) in subject's Dupuytren's contracture

Time frame:
30 days after last injection
Reported as:
Number · participants
Physician Global Assessment of Improvement
participantsXIAFLEX/XIAPEX MP JointXIAFLEX/XIAPEX PIP Joint
Very much improved1812
Much improved115
Minimally improved02
No change11
Minimally worse00
Much worse00
Very much worse00
Not done10
SecondarySubject Global Assessment of Satisfaction

Subject global assessment of overall treatment satisfaction

Time frame:
30 days after last injection
Reported as:
Number · participants
Subject Global Assessment of Satisfaction
participantsXIAFLEX/XIAPEX MP JointXIAFLEX/XIAPEX PIP Joint
Very satisfied2010
Quite satisfied95
Neither satisfied nor dissatisfied12
Quite dissatisfied01
Very dissatisfied00
Not done12
SecondaryRecurrence of Contracture

Recurrence of contracture in the joint at day 365 that was successfully treated 30 days after last injection assessed. Recurrence was defined as 20 degree or greater increase of contracture of the treated joint at day 365 or medication intervention of the treated joint between the 2 time points.

Time frame:
Day 365
Reported as:
Number · joints
Recurrence of Contracture
jointsXIAFLEX/XIAPEX
Recurrence of Contracture6

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XIAFLEX/XIAPEX—4/52 (7.7%)44/52 (84.6%)
Most frequent serious events
Most frequent serious events
EventXIAFLEX/XIAPEX
Cerebellar infarctionNervous system disorders1/52
Acute coronary syndromeCardiac disorders1/52
Acute myocardial infarctionCardiac disorders1/52
Chest painGeneral disorders1/52
Dupuytren's contractureMusculoskeletal and connective tissue disorders1/52
UrosepsisInfections and infestations1/52
Most frequent other events
Showing 10 of 11
Most frequent other events
EventXIAFLEX/XIAPEX
Oedema peripheralGeneral disorders32/52
ContusionInjury, poisoning and procedural complications23/52
Pain in extremityMusculoskeletal and connective tissue disorders16/52
Injection site painGeneral disorders10/52
PruritusSkin and subcutaneous tissue disorders10/52
Injection site haematomaGeneral disorders8/52
LymphadenopathyBlood and lymphatic system disorders8/52
Skin lacerationInjury, poisoning and procedural complications7/52
Injection site pruritusGeneral disorders5/52
Injection site swellingGeneral disorders5/52

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)XIAFLEX/XIAPEX
<=18 years0
Between 18 and 65 years20
>=65 years32
Age, Continuous
Age, Continuous(Years)XIAFLEX/XIAPEX
Mean66.5 ± 9.53
Sex: Female, Male
Sex: Female, Male(Participants)XIAFLEX/XIAPEX
Female2
Male50
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)XIAFLEX/XIAPEX
Hispanic or Latino0
Not Hispanic or Latino52
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)XIAFLEX/XIAPEX
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White52
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)XIAFLEX/XIAPEX
United States21
Australia21
United Kingdom4
Sweden6
08

Study locations

13 sites
  • HOPE Research Institute
    Phoenix, Arizona 85050, United States
  • Rockford Orthopedic Associates
    Rockford, Illinois 61107, United States
  • The Indiana Hand to Shoulder Center
    Indianapolis, Indiana 46260, United States
  • Marquette General Health System
    Marquette, Michigan 49855, United States
  • East River Professional Building
    New York, New York 10021, United States
  • Health Reserarch Institute
    Oklahoma City, Oklahoma 73109, United States
  • Hand Microsurgery and Reconstructive Orthopaedics
    Erie, Pennsylvania 16507, United States
  • Peninsula Private Hospital
    Kippa Ring, Queensland 4021, Australia
  • AusTrials Sherwood
    Sherwood, Queensland 4075, Australia
  • Emeritus Research
    Malvern East, Victoria 3145, Australia
  • Uppsala Akademiska University Hospital
    Uppsala, SE SE-751, Sweden
  • Pulvertaft Hand Center
    Derby, GB DE22 3NE, United Kingdom
  • Newcastle Upon Tyne Hospitals
    Newcastle, GB NE1 4LP, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2011
First posted
Dec 23, 2011
Start
Mar 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Feb 20, 2015
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01498640
Responsible party
Sponsor
First posted
Dec 23, 2011
Start date
Mar 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Feb 20, 2015
Last update
Oct 5, 2017

Study contacts

Veronica Urdaneta, MD, MPPH
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion